MORPHOFUNCTIONAL CHANGES OF PL ATELETS IN PATIENTS WITH T YPE II DIABETES MTLLITUS: POSSIBILITY BY α-LIPOIC ACID CORRECTION
Keywords:type II diabetes mellitus, platelets, mitochondrial dysfunction, α-lipoic acid, Dialipon-Turbo
The results of experimental and clinical studies suggest that in the pathogenesis of a significant (if not most) pathological conditions a significant role is played by mitochondrial (MD) and/or endothelial dysfunction (ED). To study the morphofunctional state of cellular organelles in healthy people and patients with pathology, almost the only objects (in the absence of surgery) are blood cells, in particular, platelets (P). Material and methods. The study of platelet ultrastructure (P) was carried out in the blood of individuals with type II diabetes mellitus (DM) before and after the course of treatment with Dialipon-Turbo — the active substance is α-lipoic acid (ALA). The group (n = 20) included patients aged 50 to 70 years of both sexes, the average blood glucose content was 11.0 ± 1.0 mmol/L. The control group consisted of 10 healthy individuals, randomized by gender and age. Results. Based on the characteristics of the T ultrastructure in patients with ALA, it can be considered that the development of the disease is accompanied by disorders of the vascular wall due to changes in the function of the serotonergic system. The tendency to thrombosis increases, which in combination with the previous, can contribute to the formation of the pathology of the cardiovascular system. A disorder in the mitochondrial (MC) apparatus of cells is direct evidence that with DM, at least in blood cells, mitochondral dysfunction (MD) develops. Under the influence of DT, the morphogenesis of MC is activated and a significant decrease in the manifestations of MD occurs. Therefore, the inclusion in the complex therapy of DM, drugs that do not affect the main pathogenetic links of the disease (hyperglycemia), are able to prevent the formation (or reduce the manifestations) of concomitant pathology caused by disorders of the vascular wall and the development of MD.
Melnikova YuS, Makarova TP. Kazan Med J 2015;96(4): 659-665. doi: http://doi.org/10.17750/KMJ2015-659.
Chin JA, Sumpio BE. Clin Podiatr Med Surg 2014;31(1): 11-26. doi: http://doi.org/10.1016/j.cpm.2013.09.001.
Danilov IP. Med News 2008; 9: 17-19.
Kolosova EN, Vasilenko IA, Kovaleva LG. Bull SB RAMS 2011; 31(2): 58-63.
Fujimi S, MacConmara MP, Maung AA, et al. Blood 2006; 107(11): 4399-406. doi: http://doi.org/10.1182/blood-2005-09-3776.
Rozova EV, Moiseenko EV. Ukr Antarctic J 2013; 12:307-314.
Kostjuk KS. Kolichestvennoe i kachestvennoe izmenenie lejkocitov pri patologicheskih procesah. 2020, available at: https://www.ncgb.by/index.php/gazeta-ncgbmeterial/41-gazeta-statiy/1055-kolichestvennoe-ikachestvennoe-izmenenie-lejkotsitov-pri-patologicheskikh-protsessakh.
Filippova OI, Koloskov AV, Stolitsa AA. Transfusiology 2012; 13(2): 493-514.
Karup VYa. Electron microscopy, Kiev, 1984: 208 p.
Tashke K. Introduction to quantitative cyto-histological morphology, Bucharest, 1980: 192 p.
Zverev AA, Zefirov TL. Statistical methods in biology: a textbook, Kazan, 2013: 42 p.
Amosova EN. Heart and Blood Vessels 2009; 2: 4-11.
Goncharuk IV, Artemova NE, Bugrova OV. Works of Conf. Orenburg State Med. University 2010: 75-78.
Lisyutenko NS, Morova NA, Tsekhanovich VN. Thrombosis of hemostasis and rheology 2016; 3: 7-13.
Lukyanova LD. Signal mechanisms of hypoxia, Moskva, 2019: 215 p.
Rochette L, Ghibu S, Muresan A, Vergely C. Canadian J Physiol Pharmacol. 2015; 93(12): 1021-1027. doi:
Dewanjee S, Das S, Das AK, et al. Eur J Pharmacol 2018; 15(833): 472-523. doi: http://doi.org/10.1016/j.ejphar.2018.06.034.
Collet JP, Montalescot G. J Cardiovasc Pharmacol Ther 2009; 14(3): 157-169. doi: http://doi.org/10.1177/1074248409339309.
Sudakova YuV. Bakeeva LE, Tsyplenkova VG. Arch Pathol 1999; 2: 15-20.
Huang J, Klionsky DJ. Cell Cycle 2007; 1(6): 1837-1849. doi: http://doi.org/10.4161/cc.6.15.4511.